Appl. No. 10/797,157 Amdt. dated December 1, 2006 Reply to Office action of August 2, 2006

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

## **Listing of Claims:**

- 1. (Currently amended) A method of modulating tumor growth comprising contacting a tumor cell with an effective amount of <u>a binding composition comprising an antigen-binding site of an antibody to p19 an antagonist of IL-23</u>.
- 2. (Currently amended) The method of Claim 1, wherein the antagonist of IL-23 binding composition inhibits or prevents tumor growth.
- 3. (Original) The method of Claim 1, wherein the tumor cell expresses IL-23.
- 4. (Currently amended) The method of Claim 1, wherein the antagonist of IL-23 comprises a binding composition that specifically binds [[a]] the polypeptide of p19 (SEQ ID NOs: 2 or 4) of SEQ ID NO: 2.
- 5. (Cancelled)
- 6. (Currently Amended) The method of Claim 4, wherein the binding composition comprises:
  - a) a polyclonal antibody;
  - b) a monoclonal antibody;
  - c) a humanized antibody, or a fragment thereof; or
  - d) an Fab, Fv, or F(ab')<sub>2</sub> fragment; or
- e) a peptide mimetic of an antibody.
- 7. (Original) The method of Claim 1, wherein the tumor cell is:
  - a) a colon cancer cell;
  - b) an ovarian cancer cell;

Appl. No. 10/797,157 Amdt. dated December 1, 2006 Reply to Office action of August 2, 2006

- c) a breast cancer cell; or
- d) a melanoma cell.
- 8. (Currently amended) A method of treating a subject suffering from a cancer or tumor comprising administering to the subject an effective amount of <u>a binding</u> composition comprising an antigen-binding site of an antibody to p19 an antagonist of IL-23.
- 9. (Currently amended) The method of Claim 8, wherein the antagonist of IL-23 binding composition inhibits:
  - a) growth of the cancer or tumor;
  - b) cachexia;
  - c) anorexia; or
  - d) angiogenesis.
- 10. (Currently amended) The method of Claim 8, wherein the antagonist of IL-23 comprises a binding composition that specifically binds [[a]] the polypeptide of p19 (SEQ ID NOs: 2 or 4) of SEQ ID NO: 2.
- 11. (Cancelled)
- 12. (Original) The method of Claim 10, wherein the binding composition comprises:
  - a) a polyclonal antibody;
  - b) a monoclonal antibody;
  - c) a humanized antibody, or a fragment thereof; or
  - d) an Fab, Fv, or F(ab')<sub>2</sub> fragment; or
- ————e) a peptide mimetic of an antibody.
- 13. (Original) The method of Claim 8, wherein the cancer or tumor is of the:
  - a) gastrointestinal tract;
  - b) respiratory tract;

Appl. No. 10/797,157 Amdt. dated December 1, 2006 Reply to Office action of August 2, 2006

- c) reproductive system; or
- d) endocrine system.
- 14. (Original) The method of Claim 8, wherein the cancer or tumor is:
  - a) colon cancer;
  - b) ovarian cancer;
  - c) a melanoma; or
  - d) breast cancer.